1 |
P.D. Henry, Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem, Am. J. Cardioi., 46, 1047-1058 (1980)
DOI
ScienceOn
|
2 |
E.M. Sorkin, S.P Clissold and R.N. Brogden, Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders, Drugs, 30, 182-274 (1985)
DOI
ScienceOn
|
3 |
D.G. Walter, B.S. Gruchy, AG. Renwick and e.E George, The fIrst pass metabolism of nifedipine in man, Br. J. Clin. Pharmacoi., 18, 951-954 (1984)
DOI
ScienceOn
|
4 |
K.D. Raemsch and J.C. Sommer, Pharmacokinetics and metabolism of nifedipine, Hypertension., 5, 18-24 (1983)
|
5 |
E.P. Guengerich, W.R. Brian and M. Iwasaki, et ai., Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4, J. Med. Chern., 4, 1838-1844 (1991)
|
6 |
C. Iribarne, L.G. Dr ano, J.F Bardou, G. M nez and F. Berthou, Interaction of methadone with substrates of human hepatic cytochrome P450 3A4, Toxicology, 117, 13-23 (1997)
DOI
ScienceOn
|
7 |
M.M. Gottesman and I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427 (1993)
DOI
ScienceOn
|
8 |
L.-S.L. Gan, M.A. Moseley, B. Khosla, P.E. Augustijns, T.P Bradshaw, R.W Hendren and D.R Thakker, CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos., 24, 344-349 (1996)
|
9 |
P.B. Watkins, The barrier function of CYP3A4 and P-glycoprotein in the small bowel, Adv. Drug Deliv. Rev., 27, 161-170 (1996)
DOI
ScienceOn
|
10 |
V.H. Wacher, I.A Silverman, Y. Zhang and L.Z. Benet, Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics, J. Pharm. Sci., 87, 1322-1330 (1998)
DOI
|
11 |
K. Ito, H. Kusuhara and Y Sugiyama, Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach, Pharm. Res., 16, 225-231 (1999)
DOI
ScienceOn
|
12 |
P.M. Chaudhary, and I.B. Robinson, Expression and activity of P-glycoprotein, a multidrug efllux pump, in human hematopoietic stem cells, Cell, 66, 85-94 (1991)
DOI
ScienceOn
|
13 |
I Van Asperen, O. Van Tellingen, A Sparreboom, A.H. Schinkel, P. Borst, W.J. Nooijen and J.H. Beijnen, Euhanced oral bilavailability of diltiazem in mice treated with the pglycoprotein blocker, Br. J. Cancer; 76, 1181-1183 (1997)
DOI
ScienceOn
|
14 |
J.L. Biedler and H. Riehm, Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies, Cancer Res., 30, 1174-1184 (1970)
|
15 |
J.M. Ford, Modulators of multidrug resistance preclinical studies, Bernatol. Oncol. Clin. N. Am., 9, 337-361 (1995)
|
16 |
T. Endo, O. Kimura and M. Sakata, Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PKl, and OK, Toxicol. Appl. Pharmacol., 185, 166-171 (2002)
DOI
ScienceOn
|
17 |
N. Hokama, N. Hobara, M. Sakai, H. Kameya, S. Ohshiro and M. Sakanashi, fufluence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats, J. Pharm. Pharmacol., 54, 821-825 (2002)
DOI
ScienceOn
|
18 |
U. Takahama, Inhibition of lipoxygenase-dependent lipid peroxidation by quercetin: mechanism of antioxidative function. Phytochemistry, 24, 1443-1446 (1985)
DOI
ScienceOn
|
19 |
E.N. Frankel, J.B. German, E. Parks and J.E. Kinsella, Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wind, The Lancet., 341, 454-457 (1993)
DOI
ScienceOn
|
20 |
M.T. Murray, Quercetin: Nature's antihistamine, Better. Nutrition., 60, 10-16 (1998)
|
21 |
W. Davis, M.S. Lamson, S. Matthew and N.D. Brignall, Antioxidants cancer: Quercetin. Alternative Medicine Review. 5, 196-208 (2000)
|
22 |
D.R. Ferry, A Smith, J. Malkhandi, D.W Fyfe, P.G. deTakats, D. Anderson, J Baker and DR Kerr, Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition, Clinical Cancer Research, 2, 659-668 (1996)
|
23 |
G. Soambia, F.O. Ranellett, P.B. Panici, D.R Vmcenzo, G. Bonanno, G. Frrandina, M. Piantelli, S. Bussa, C. Rurni and M. Ciantriglia, Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human. breast-cancer cell line: P-glycoprotein as a possible target, Cancer Chemother. Pharmacol., 36, 448-450 (1995)
DOI
ScienceOn
|
24 |
J.C. Kolars, P. Schmiedlin-Ren, W.O. Dobbins 3rd, J. Schuetz, S.A Wrighton and P.B. Watkins, Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology, 102, 1186-1198 (1992)
|
25 |
N. He and T. Edeki, The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes, Am. J. Ther., 11, 206-212 (2004)
DOI
ScienceOn
|
26 |
G.N. Kumar, UK Walle and T. Walle, Cytochrome P450 3A-mediated human liver microsomal taxol 6, alpha-hydroxylation, J. Pharmacol. Exp. Ther., 268, 1160-1165 (1994)
|
27 |
A. Rahman, K.R. Korzekwa, J Grogan, F.J. Gonzalez and J.W. Harris, Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8, Cancer Res., 54, 5543-5546 (1994)
|
28 |
A. Junichi, Y. Isamu, W Takahiro, O. Yoshimitsu, T. Takahiko, T. Sanae, Y Kenichi, T. Toshiaki and K Koichi, Effects of grapefruit juice on the pharmacokinetics of the calcium channel blockers nifedipine and nisoldipine, Current Therapeutic Research, 59, 619-634 (1998)
DOI
ScienceOn
|
29 |
J. Rashid, C. McKinstry, A.G. Renwick, et aI., Quercetin, an in vitro inhibitor ofCYP3A, does not contribute to the interaction between nifedipine and grapefruit juice, Br. J. Clin. Pharmacol., 36, 460-463 (1993)
DOI
ScienceOn
|
30 |
A Miniscalco, J. Lundahl, C.G. Regardh. et ai., Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice, J. Pharmacol. Exp. Ther., 261, 1195-1199 (1992)
|
31 |
J.S. Grundy, R. Kherani and R.T. Foster, Sensitive high-performance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection, J. Chrornatogr. B. Biomed. Appl., 654, 146-151 (1994)
DOI
ScienceOn
|
32 |
M.L. Rocci and WI Iusko, LAGRAN program for area and moments in pharmacokinetic analysis, Computer Programs in Biomedicine, 16, 203-209 (1983)
DOI
ScienceOn
|
33 |
J.P. Fruehauf and A Manetta, Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDRI expression, Contrib. Gynecol. Obstet., 19, 39-52 (1994)
|
34 |
P.B. Watkins, S.A. Wrighton, E.G. Schuetz, D.T. Molowa and PS. Guzelian, IdentifIcation of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man, J. Clin. Invest., 80, 1029-1036 (1987)
DOI
|
35 |
C.H. Choi, N. Romiti, F. Cervelli and R. Tongiani, Effect of flavonols on P-glycoprotein activity in cultured rat hepatocytes, Life Sciences, 57, 1741-1750 (1995)
DOI
ScienceOn
|
36 |
J.S. Choi, BW. Jo and YC. Kim, Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J. Pharm. Biophann., 57, 313-318 (2004)
DOI
ScienceOn
|